Company profile
NIQS Tech | Truly accurate and non-invasive glucose monitoring
NIQS Tech | Truly accurate and non-invasive glucose monitoring
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ1NjMzOTEzNGFkaXF6a2N4
Published 25 Feb 2025 01:55
AD01 | Transaction MzQzNzcxOTgxMmFkaXF6a2N4
Published 30 Sep 2024 11:15
Company registered at Companies House
NIQS Tech Limited is a quantum technology spin-out from the University of Leeds and was officially incorporated in July 2022. Our patented sensing technology was developed in the leading research groups of Prof. Gin Jose and Dr Almut Beige. Our work represents the next generation of optical sensors that enables real-time, accurate biomarker monitoring, without breaking the skin surface or drawing blood samples.
Rather than using traditional approaches to detecting glucose concentrations in the body which have numerous limiting factors, NIQS is utilising a novel optical appraoch. Using novel interactions known as ultralong-range dipole-dipole interactions. These interactions form our non-invasive sensing mechanism that enable us to perform targeted measurements within the system or sample we wish to investigate. We are able to harness these ultralong-range interactions using our unique sensor design (patent-pending). By performing targeted measurements, it means we are able to mitigate and reduce the effect of skin thickness, skin tone, and hydration levels to effectively provide a more accurate and reliable measurement compared to the spectroscopic approaches.
1 May 2024 to 30 Apr 2025
There is a compelling need for affordable and accessible technologies that can aid in the early diagnosis of medical conditions to prevent ill-health by reducing the existing and future burden of disease, ensuring everyone can live long, healthy lives. These types of solutions are equally important for monitoring long-term health conditions that can be co...
1 Dec 2022 to 31 May 2024
The objective of the project is to conduct in-vitro feasibility studies for a second- generation quantum sensor, codenamed LUX1, that optically monitors glucose in a revolutionary new way. Unlike currently available sensors, LUX1 will allow people living with diabetes (PLWD) to conveniently measure real-time glucose levels without drawing blood or breakin...
